@article{6e487ac6b174401e8d3baf83d13cb571,
title = "Clonal evolution of AML on novel FMS-like tyrosine kinase-3 (FLT3) inhibitor therapy with evolving actionable targets",
abstract = "For acute myeloid leukemia (AML), identification of activating mutations in the FMS-like tyrosine kinase-3 (FLT3) has led to the development of several FLT3-inhibitors. Here we present clinical and next generation sequencing data at the time of progression of a patient on a novel FLT3-inhibitor clinical trial (ASP2215) to show that employing therapeutic interventions with these novel targeted therapies can lead to consequences secondary to selective pressure and clonal evolution of cancer. We describe novel findings alongside data on treatment directed towards actionable aberrations acquired during the process. (Clinical Trial: NCT02014558; registered at: 〈. https://clinicaltrials.gov/ct2/show/NCT02014558〉).",
keywords = "ASP2215, Acute Leukemia, Clonal evolution, FMS-like tyrosine kinase-3 (FLT3) inhibitors, Philadelphia chromosome (BCR-ABL), Ponatinib",
author = "Kasi, {Pashtoon M.} and Litzow, {Mark R.} and Patnaik, {Mrinal M.} and Hashmi, {Shahrukh K.} and Naseema Gangat",
note = "Funding Information: The clinical trial component was supported through funding from Astellas Pharma Global Development (APGD). All other support for the research and testing was through division of hematology and center of individualized medicine (CIM), Mayo Clinic, Rochester, MN, USA. No other conflicts of interest to report. Funding Information: We are deeply indebted to the patient and his parents for allowing us to share his case. Written informed consent was obtained. Thanks are also due to the multiple care providers and nursing staff who have been diligently taking care of the patient for more than a year now. The clinical trial component was supported through funding from Astellas Pharma Global Development (APGD) Clinical trial number 2215-CL-0101; Clinical trial information: NCT02014558; https://clinicaltrials.gov/show/NCT02014558 . All other support for the research and testing was through division of hematology and center of individualized medicine (CIM), Mayo Clinic, Rochester, MN, USA. Thanks are also due to Dr. Abraham, Roshini S., Ph.D., Professor of Laboratory Med/Pathology and Medicine, College of Medicine, Mayo Clinic, Rochester for help and guidance with other testing that was pursued. Publisher Copyright: {\textcopyright} 2016 The Authors.",
year = "2016",
doi = "10.1016/j.lrr.2016.01.002",
language = "English (US)",
volume = "5",
pages = "7--10",
journal = "Leukemia Research Reports",
issn = "2213-0489",
publisher = "Elsevier Limited",
}